Clin Gastroenterol Hepatol. 2022 Jul;20(7):1609-1612.e1. doi: 10.1016/j.cgh.2021.12.045.Epub 2022 Jan 6.

Sarah Frey ¹, Reezwana Chowdhury ², Caoilfhionn M Connolly ³, William A Werbel ⁴, Dorry L Segev ⁵, Alyssa M Parian ⁶, IBD GROUP ²

Collaborators

IBD GROUP: 

Evangelos Tsipotis, Sharon Dudley-Brown, Mark Lazarev, Joanna M Melia, Brindusa Truta, Huimin Yu, Florin M Selaru

Author information

¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

²Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.

³Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.

⁴Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.

⁵Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.

⁶Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: aparian1@Jhmi.edu.

Abstract

Patients with inflammatory bowel disease (IBD) are recommended to receive vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), regardless of their immunosuppression status. Immunosuppressive medications represent a mainstay of therapy in moderate to severe IBD; however, their impact on the SARS-CoV-2 vaccine response remains unclear. Studies thus far have shown that patients with IBD on various therapies had detectable antibody responses after standard vaccinations.^1-5 To date, one study has examined the kinetics of antibody response at 3 months after vaccination in patients with IBD, but data beyond this time point are not yet available.⁶ The aim of this study was to assess anti-spike antibody response 6 months after completion of standard SARS-CoV-2 vaccination in patients with IBD. Secondarily, we observed antibody kinetics over 6 months in a subset of patients post-vaccination.